m^(6)A修饰在肝细胞癌发生发展及治疗中作用的研究进展  

Advances in role of m^(6)A modification in development and treatment of hepatocellular carcinoma

作　　者：黄伟健[1] 李柳艳 曾达通 危丹明[2] 熊丹丹[2] HUANG Weijian;LI Liuyan;ZENG Datong;WEI Danming;XIONG Dandan(Department of Pathology,Red Cross Hospital of Yulin City,Yulin 537000,China;Department of Pathology,First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西玉林市红十字会医院病理科,广西玉林537000 [2]广西医科大学第一附属医院病理科,广西南宁530021

出　　处：《中国病理生理杂志》2023年第9期1702-1707,共6页Chinese Journal of Pathophysiology

基　　金：广西自然科学基金资助项目(No.2022GXNSFBA035657);广西壮族自治区卫生健康委员会自筹经费科研课题(No.Z20210764)。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)是世界上第六大最常见的恶性肿瘤,也是肿瘤相关死亡的第四大原因[1]。据报道,2018年全球新增病例约841000例,死亡病例约781000例[2]。由于其早期症状隐匿,多数患者确诊时已处于疾病晚期,因此HCC的发病率与死亡率之比接近1[3]。目前,HCC潜在的分子发病机制在很大程度上尚不清楚[4]。探索HCC发生发展的分子机制对HCC早期诊断、精准治疗至关重要。N^(6)-methyladenosine(m^(6)A)modification of RNA is the most abundant modification in most eukary-otic RNAs and is involved in almost all stages of the RNA lifecycle,playing crucial roles in regulating RNA expression,splicing,translation,stability,degradation,etc.Recent studies have suggested that m^(6)A modification plays a significant role in the pathogenesis of hepatocellular carcinoma(HCC);however,the underlying molecular mechanisms remain un-clear.This review summarizes the current research progress on the role of m^(6)A modification in HCC progression,drug re-sistance,radiofrequency ablation therapy,and immunotherapy,aiming to provide valuable insights for the precise treat-ment of HCC patients.

关 键 词：肝细胞癌 RNA甲基化修饰 m^(6)A修饰 治疗 

分 类 号：R735.7[医药卫生—肿瘤] R363[医药卫生—临床医学]